Christina de Rivera
University of Toronto
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Christina de Rivera.
British Journal of Nutrition | 2010
Yuanlong Pan; Brian T. Larson; Joseph A. Araujo; Winnie Lau; Christina de Rivera; Ruben D. Santana; Asa Gore; Norton W. Milgram
The present study focused on the hypothesis that dietary supplementation with medium-chain TAG (MCT) will improve cognitive function in aged dogs by providing the brain with energy in the form of ketones. Aged Beagle dogs were subjected to a baseline battery of cognitive tests, which were used to establish cognitively equivalent control or treatment groups. The dogs in the treatment group were maintained on a diet supplemented with 5.5 % MCT. After an initial wash-in period, all the dogs were tested with a battery of cognitive test protocols, which assessed sequentially landmark discrimination learning ability, egocentric visuospatial function and attention. The groups were maintained on the diets for 8 months. The MCT-supplemented group showed significantly better performance in most of the test protocols than the control group. The group differences also varied as a function of task difficulty, with the more difficult task showing greater supplementation effects than the easier tasks. The group given the MCT supplement showed significantly elevated levels of beta-hydroxybutyrate, a ketone body. These results indicate, first, that long-term supplementation with MCT can have cognition-improving effects, and second, that MCT supplementation increases circulating levels of ketones. The results support the hypothesis that brain function of aged dogs can be improved by MCT supplementation, which provides the brain with an alternative energy source.
Frontiers in Aging Neuroscience | 2014
Shikha Snigdha; Christina de Rivera; Norton W. Milgram; Carl W Cotman
Exercise has been shown to reduce age-related losses in cognitive function including learning and memory, but the mechanisms underlying this effect remain poorly understood. Memory formation occurs in stages that include an initial acquisition phase, an intermediate labile phase, and then a process of consolidation which leads to long-term memory formation. An effective way to examine the mechanism by which exercise improves memory is to introduce the intervention (exercise), post-acquisition, making it possible to selectively examine memory storage and consolidation. Accordingly we evaluated the effects of post-trial exercise (10 min on a treadmill) on memory consolidation in aged canines both right after, an hour after, and 24 h after acute exercise training in concurrent discrimination, object location memory (OLM), and novel object recognition tasks. Our study shows that post-trial exercise facilitates memory function by improving memory consolidation in aged animals in a time-dependent manner. The improvements were significant at 24 h post-exercise and not right after or 1 h after exercise. Aged animals were also tested following chronic exercise (10 min/day for 14 consecutive days) on OLM or till criterion were reached (for reversal learning task). We found improvements from a chronic exercise design in both the object location and reversal learning tasks. Our studies suggest that mechanisms to improve overall consolidation and cognitive function remain accessible even with progressing age and can be re-engaged by both acute and chronic exercise.
Journal of Alzheimer's Disease | 2011
Joseph A. Araujo; Donald K. Ingram; Johan Sandin; Christina de Rivera; Norton W. Milgram
Similar to patients with Alzheimers disease (AD), dogs exhibit age-dependent cognitive decline, amyloid-β (Aβ) pathology, and evidence of cholinergic hypofunction. The present study sought to further investigate the role of cholinergic hypofunction in the canine model by examining the effect of the cholinesterase inhibitors phenserine and donepezil on performance of two tasks, a delayed non-matching-to-position task (DNMP) designed to assess working memory, and an oddity discrimination learning task designed to assess complex learning, in aged dogs. Phenserine (0.5 mg/kg; PO) significantly improved performance on the DNMP at the longest delay compared to wash-out and partially attenuated scopolamine-induced deficits (15 μg/kg; SC). Phenserine also improved learning on a difficult version of an oddity discrimination task compared to placebo, but had no effect on an easier version. We also examined the effects of three doses of donepezil (0.75, 1.5, and 6 mg/kg; PO) on performance of the DNMP. Similar to the results with phenserine, 1.5 mg/kg of donepezil improved performance at the longest delay compared to baseline and wash-out, indicative of memory enhancement. These results further extend the findings of cholinergic hypofunction in aged dogs and provide pharmacological validation of the canine model with a cholinesterase inhibitor approved for use in AD. Collectively, these studies support utilizing the aged dog in future screening of therapeutics for AD, as well as for investigating the links among cholinergic function, Aβ pathology, and cognitive decline.
British Journal of Nutrition | 2013
Yuanlong Pan; Joseph A. Araujo; Joey Burrows; Christina de Rivera; Asa Gore; Sandeep Bhatnagar; Norton W. Milgram
Cognitive dysfunction syndrome is a major disease affecting old cats and is the consequence of severe and irreversible loss of brain cells and brain atrophy. The present study focused on the hypothesis that the optimal strategy for promoting successful brain ageing is to target risk factors associated with brain ageing and dementia. We used a nutritional strategy involving supplementation with a blend of nutrients (antioxidants, arginine, B vitamins and fish oil) to test this hypothesis. Middle-aged and old cats between 5·5 and 8·7 years of age were assigned to cognitively equivalent control or treatment groups based on prior cognitive experience and performance on baseline cognitive tests. The cats in the treatment group were maintained on a diet supplemented with the nutrient blend and the cats in the control group were maintained on the identical base diet without the additional supplementation. After an initial wash-in period, all cats were tested on a battery of cognitive test protocols. The cats fed the test diet showed significantly better performance on three of four test protocols: a protocol assessing egocentric learning, a protocol assessing discrimination and reversal learning and a protocol focused on acquisition of a spatial memory task. The results support the hypothesis that brain function of middle-aged and old cats can be improved by the nutrient blend that was selected to minimise or eliminate the risk factors associated with brain ageing and dementia.
Experimental Gerontology | 2009
Lori-Ann Christie; Wycliffe O. Opii; Elizabeth Head; Joseph A. Araujo; Christina de Rivera; Norton W. Milgram; Carl W. Cotman
Previous work has shown that a diet enriched with antioxidants and mitochondrial co-factors improves cognition in aged dogs, which is accompanied by a reduction in oxidative damage in the brain. The objective of the present study was to assess the effects of supplementation with mitochondrial co-factors on cognition and plasma protein carbonyl levels in aged dogs. Specifically, we aimed to test whether the individual or combined action of lipoic acid (LA) and acetyl-l-carnitine (ALCAR) could account for the beneficial effects of the enriched diet that contained both plus antioxidants. Dogs were given LA or ALCAR, alone and then in combination and cognition was assessed using a spatial learning task and two discrimination and reversal paradigms. Dogs receiving the ALCAR supplement showed an increase in protein carbonyl levels that was associated with increased error scores on the spatial task, and which was reduced upon additional supplementation with LA. We did not observe significant positive effects on cognition. The present findings suggest that short-term supplementation with LA and ALCAR is insufficient to improve cognition in aged dogs, and that the beneficial effects of the full spectrum diet arose from either the cellular antioxidants alone or their interaction with LA and ALCAR.
Progress in Neuro-psychopharmacology & Biological Psychiatry | 2005
Christina de Rivera; Isabelle Boutet; Steven C. Zicker; Norton W. Milgram
Tasks requiring visual discrimination are commonly used in assessment of canine cognitive function. However, little is known about canine visual processing, and virtually nothing is known about the effects of age on canine visual function. This study describes a novel behavioural method developed to assess one aspect of canine visual function, namely contrast sensitivity. Four age groups (young, middle aged, old, and senior) were studied. We also included a group of middle aged to old animals that had been maintained for at least 4 years on a specially formulated food containing a broad spectrum of antioxidants and mitochondrial cofactors. Performance of this group was compared with a group in the same age range maintained on a control diet. In the first phase, all animals were trained to discriminate between two high contrast shapes. In the second phase, contrast was progressively reduced by increasing the luminance of the shapes. Performance decreased as a function of age, but the differences did not achieve statistical significance, possibly because of a small sample size in the young group. All age groups were able to acquire the initial discrimination, although the two older age groups showed slower learning. Errors increased with decreasing contrast with the maximal number of errors for the 1% contrast shape. Also, all animals on the antioxidant diet learned the task and had significantly fewer errors at the high contrast compared with the animals on the control diet. The initial results suggest that contrast sensitivity deteriorates with age in the canine while form perception is largely unaffected by age.
Journal of Feline Medicine and Surgery | 2017
Christina de Rivera; Jacqui Ley; Bill Milgram; Gary M. Landsberg
Objectives The objectives of this study were: (1) to develop a laboratory-based model to assess fear and anxiety in cats using the feline open-field test (OFT) and the feline human interaction test (HIT); and (2) to validate the model using diazepam, a known anxiolytic. Methods Laboratory-housed cats (n = 41) were first classified as fearful, mildly fearful or non-fearful by a technician familiar with the cats and also by veterinary behaviorists (GL, JL), by assessing the cats’ behavior in their home rooms. In experiment 1, each cat’s behavior was assessed in an OFT and an HIT. In experiment 2, after administration of the anxiolytic diazepam, a subset of the cats was re-tested. Results In experiment 1, the OFT revealed significant group effects on two measures: duration of inactivity, and vocalization. Fearful animals had significantly longer periods of inactivity than non-fearful animals. Non-fearful and mildly fearful cats vocalized more frequently than fearful cats. In the HIT, fearful cats travelled less than non-fearful and mildly fearful cats. Fearful and mildly fearful animals had significantly longer durations of inactivity, and non-fearful and mildly fearful cats had a significantly higher frequency of vocalization compared with fearful cats. In experiment 2, in the OFT, treatment with diazepam caused an increase in distance travelled, shorter durations of inactivity, and more frequent inactivity and vocalization. In the HIT, diazepam increased distance travelled and decreased duration of inactivity. Fearful cats spent significantly less time near the human compared with non-fearful cats, and this persisted under diazepam. Conclusions and relevance The feline OFT and feline HIT can be used jointly to assess the effects of medications or other therapies on fear and anxiety in the domestic cat.
Progress in Neuro-psychopharmacology & Biological Psychiatry | 2005
Candace J. Ikeda-Douglas; Christina de Rivera; Norton W. Milgram
This special journal issue is based on the proceedings of the 10th annual meeting on canine cognition and neuropathology held in Toronto, Ontario, Canada on June 14th and 15th, 2004. The first such meeting, in Toronto, Ontario in 1995, was aimed at providing a forum for researchers from three Labs, Dr. C.W. Cotman of the University of California at Irvine, N.W., Milgram of University of Toronto, and B. Muggenburg of Lovelace Respiratory and Research Institute in Albuquerque, New Mexico, sharing a common interest in the development of a dog model of cognitive aging. We have subsequently met yearly, with progressively increasing attendance and more widespread participation, reflecting an increased scientific awareness and acceptance of the dog model. The articles covered in this issue were based on both oral presentations and posters, given at the meeting. The underlying theme of this year’s meeting was practical applications, which provides an indication of growing maturity of the canine model. The topic issue consists of three sections. The first focuses on recent developments in advancing the canine model. The second deals with other models, including rodent and primate models, and also includes recent comparative neuropsychological data obtained from human subjects. The final section is concerned with practical applications of the canine model, including the assessment of efficacy of interventions. 2. Recent developments in advancing the canine model of cognitive aging
Archive | 2017
Joseph A. Araujo; Jessica Baulk; Christina de Rivera
Alzheimer’s disease is the most common cause of dementia in humans and is rapidly becoming an unmet medical need of epidemic proportions. Although billions of dollars have been allocated to this cause, more than 190 putative Alzheimer’s disease drugs have failed in the clinic, exemplifying the high risk-to-reward ratio of therapeutic development. One factor implicated in this high failure rate is the limitation of animal models to accurately predict clinical outcomes. The fact that some of these models, such as transgenic mice, have a 100% failure rate for predicting clinical outcomes of putative drugs exemplifies their limitations and the need for additional models that better recapitulate the multifactorial nature of Alzheimer’s disease progression. Aged dogs naturally develop Alzheimer’s-like neuropathological changes, as well as cognitive-domain specific impairments consistent with early stages of Alzheimer’s disease progression. Moreover, cross-sectional data in differentially aged dogs suggests that Alzheimer’s relevant biomarker changes are also found in dogs and could be used to monitor early stage Alzheimer’s-like disease progression. The aged dog model accurately predicted the clinical outcome of both the gold standard symptomatic Alzheimer’s disease therapeutic, donepezil, and the failure of active fibrillary amyloid vaccination strategies. The aged dog, therefore, provides a valuable preclinical animal model for assessing Alzheimer’s disease therapeutics with demonstrable translational value for predicting clinical outcomes. Given the translational validity of the model, it is likely that Alzheimer’s disease clinical research could also be used for improving care of senior dogs.
Journal of Feline Medicine and Surgery | 2017
Gary M. Landsberg; Bill Milgram; Isabelle Mougeot; Stephanie Kelly; Christina de Rivera
Objectives This study assessed the anxiolytic effectiveness of a test diet (Royal Canin Feline Calm diet) supplemented with L-tryptophan and alpha-casozepine. Methods Subjects were 24 cats that were classified as mildly or markedly fearful based on the presence of a person in their home room. Three different protocols were used to assess anxiety: (1) evaluation of the response to a human in the cat’s home room (home room test); (2) analysis of the response to placement in an empty test room (open-field test); and (3) analysis of the response to an unfamiliar human (human interaction test). All three protocols were first run at baseline, and the results were used to assign the animals to control and test diet groups that showed equivalent fear and anxiety. Both groups were retested on the three protocols after 2 weeks (test 1) and again after 4 weeks (test 2). Results The diet groups differed for two behavioral measures in the open-field test: inactivity duration and inactivity frequency. The control group showed statistically significant increases in inactivity duration between baseline and test 1 and baseline and test 2, while the group fed the test diet showed a marginally not significant decrease in inactivity duration between baseline and test 1 and a not significant decrease for test 2. There was also a significant increase in inactivity frequency between baseline and test 1 in the test diet group and marginally not significant decrease in the control group. There were no differences between groups in the approach of the cats toward people for the home room test and the human interaction test. Conclusions and relevance These results suggest that the test diet reduced the anxiety response to placement in an unfamiliar location, but that fear in the presence of an unfamiliar person was not counteracted by the diet.